High-Dosed Intravenous Iron Replacement Therapy Does Not Hinder Drug-Induced Amelioration of Disease Activity in IBD Patients with Iron Deficiency Anemia

    January 2018 in “ Journal of Crohn s and Colitis
    Jürgen M. Stein, S Vollmer, W Klemm, Nip Kerry, S Weber-Mangal, Axel Dignaß
    Studysummary This study found that high-dose intravenous ferric carboxymaltose may reduce inflammatory activity in patients with inflammatory bowel disease and iron deficiency anaemia, as evidenced by decreased CRP levels and improved clinical disease indices.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →